Select Page

NEWS & PUBLICATIONS

Contents:

Press Releases

CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease

Itanapraced blocks LRRK2 expression and LRRK2-mediated neurotoxicity Itanapraced ready to advance to Phase 2 in Parkinson’s disease patients with and without genetic mutation NEW YORK and SINGAPORE, Dec. 10, 2018 (GLOBE NEWSWIRE) — CERESPIR INCORPORATED a... read more

CereSpir Incorporated Obtains New Patent from USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer’s Disease

NEW YORK, N.Y. –  CereSpir™ Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the company has obtained a new patent from the United States Patent and Trademark Office (USPTO)... read more

CereSpir Incorporated Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer’s Disease

NEW YORK, N.Y. – CereSpir™ Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the company has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug... read more